Arvid Söderhäll, Empros Pharma CEO

Swedish biotech un­veils topline da­ta on weight loss drug de­signed for main­te­nance af­ter GLP-1s

Em­pros Phar­ma’s oral weight loss drug on­ly de­liv­ered an av­er­age 8% body weight re­duc­tion in its Phase IIb test. So it can’t bat­tle with big …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.